Pro-inflammatory cytokines and immune modulation pathways

Pro-inflammatory cytokines and immune modulation pathways encompass a broad array of signaling molecules and biochemical cascades that drive the inflammatory response. Central to these pathways are cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which act as intercellular messengers to activate immune cells and induce the production of additional inflammatory mediators (StatPearls, 2023). These molecules bind to specific receptors, initiating intracellular signaling through pathways like the Janus kinase/signal transducer and activator of transcription (JAK/STAT) or Nuclear Factor-kappa B (NF-κB) systems (Nature Reviews Immunology, 2018). While essential for host defense against pathogens, dysregulated or chronic activation of these pathways is a primary driver of autoimmune diseases, chronic inflammatory conditions, and systemic inflammatory response syndromes (PubMed, 2012). Therapeutic strategies focus on precisely modulating these pathways using monoclonal antibodies to neutralize cytokines or small molecules to inhibit signaling enzymes, thereby reducing tissue damage while managing the inherent risk of increased susceptibility to infection.

Other names

Inflammatory cytokinesImmune signaling pathwaysPro-inflammatory mediatorsCytokine network

Drugs targeting these pathways typically act by neutralizing circulating ligands (monoclonal antibodies), blocking cell-surface receptors (receptor antagonists), or inhibiting intracellular signaling cascades such as the JAK/STAT or NF-kappaB pathways to reduce the production and effect of inflammatory mediators.